PubMed Health⌕ Search

Biomedical subjects

S Murugasampillay

Publications and source records attributed to S Murugasampillay.

5 recordsLinked to original sources
PubMed2001

Factors associated with measles complications in Gweru, Zimbabwe.

OBJECTIVE: To investigate factors associated with complications or death among measles cases. DESIGN: A cross-sectional study. SETTING: Health facilities in the city of Gweru, Zimbabwe. SUBJECTS: Six hundred and thirty seven measles cases randomly selected from measles surveillance data. MAIN OUTCOME MEASURES: (a) Associations of respiratory complications and diarrhoea with death among complicated cases; (b) associations of age at infection, gender of cases and vaccination status of cases with occurrence of either respiratory complications or diarrhoea or death among measles cases. RESULTS: Among cases with respiratory complications, twenty two (29%) had died, while five (5%) had died among those with diarrhoea (OR=7.06,95% CI=2.55-22.35, p<0.001). On rates of respiratory complications among cases, age groups 24-59 and 60+ months were protective by 57% (95% CI=11-79%) and 76% (95% CI=52-88%) respectively compared to the age group <24 months, and vaccination was protective by 42% (95% CI=2-65%) compared to those unvaccinated. Concerning rates of diarrhoea among cases, the age group 60+ months was protective by 80% (95% CI=62-89%) compared to age group <60 months, while vaccination was protective by 64% (95% CI=42-77%) compared to those unvaccinated. With respect to rates of mortality among cases, age was protective by six per cent (95% CI=3-9 %) for every year older. CONCLUSION: It was concluded that: (a) the risk of death was higher in cases with respiratory complications than diarrhoea; (b) the risk of complications and death was inversely related to age at infection and older age groups were protective against occurrence of complications or death; (c) the risk of complications was higher in unvaccinated cases and vaccination was protective against occurrence of complications.

Age Factors↗
PubMed1997

Measles complications: the importance of their management in reducing mortality attributed to measles.

OBJECTIVE: To determine the effect of rates of complications among cases and management of complicated cases on measles case fatality rates. DESIGN: Measles disease surveillance. SETTING: City of Gweru, Department of Health. SUBJECTS: Children aged zero to 15 years. MAIN OUTCOME MEASURES: Case fatality rates. RESULTS: Measles case fatality rates declined from 47.6 in 1967 to zero in 1989. Between 1967 and 1978 respiratory infections were the predominant complications (66.5%), while after 1979 diarrhoea was the predominant complications (60.6%). A significant partial correlation coefficient was observed between rates of mortality among complicated cases and case fatality rates (r = 0.89, df = 20, p < 0.001). CONCLUSION: Good management of complicated cases may have contributed towards the decline in measles case fatality rates.

Adolescent↗
PubMed1997

Comparison of protection afforded by single measles vaccination and late revaccination schedules.

An intervention study compared the protection afforded vaccinees by single measles vaccination and late revaccination schedules in 1990-94. During the intervention a single revaccination (after initial vaccination at nine months of age) was applied to children at any point in time between 12 and 23 months of age. Cases of measles aged 10-23 months were identified through an active surveillance system and in this period 5, 11 and 11 cases of revaccinated, single vaccination and unvaccinated children were identified. Measles incidence rates were 392.2-415.6 (mean = 405.6, SD = 6.7), 75.4-112.1 (median = 91.7, SD = 13.3) and 12.8-15.2 (mean = 13.9, DS = 0.99) per 100,000 population in children who were unvaccinated, with single vaccination and revaccinated respectively. Relative risk of contracting measles in children who were unvaccinated or with single vaccination was 26.5-32.5 (mean = 29.4, SD = 2.3) and 5.8-8.8 (mean = 6.8, SD = 1.2) respectively compared with revaccinated children. Vaccine efficacies that were determined were 73-81% (mean = 77.2, SD = 2.9) and 96.2-96.9% (mean = 96.6, SD = 0.27) for single vaccination and late revaccination schedules respectively. It was concluded that late revaccination affords vaccinees better protection than single vaccination through improvement in vaccine.

Age Factors↗
PubMedDate not supplied

Malaria and HIV co-infection: available evidence, gaps and possible interventions.

OBJECTIVES: To review the evidence of association between malaria and HIV/AIDS co-infection for purposes of developing strategies for malaria control. DESIGN: Desktop review of literature. SETTING: Harare, Zimbabwe. MAIN OUTCOME MEASURES: Response to treatment, development of severe malaria, malarial immunological response in HIV/AIDS positive people and incidence of malaria in HIV/AIDS positive individuals. RESULTS: HIV-1 infection increases the incidence of Plasmodium falciparum parasitaemia and is associated with the development of severe malaria, commonly anaemia, cerebral malaria and high parasite density (OR = 2.56; 95% CI = 1.53 to 4.29; p < 0.001). The efficacy of chloroquine and sulphadoxine-pyrimethamine in reducing placental malaria in HIV-1 positive pregnant women was impaired compared to HIV-1 negative pregnant women. However, the situation in non-gravid HIV-1 positive people as regards efficacy of chloroquine and sulphadoxine-pyrimethamine prophylaxis is not known. Also not known is the relationship between malaria parasitaemia without symptoms and HIV-1 infection, the results of which may provide useful information regarding malaria control and prevention in HIV-1 positive people. CONCLUSIONS: HIV-1 positive people staying in malaria endemic areas are at risk of developing severe malaria. Malaria prevention using insecticide-treated bednets and indoor residual house spraying may be the best available options for these people. Chloroquine and sulphadoxine-pyrimethamine prophylaxis require further studies to verify their efficacy, in the presence of HIV-1/AIDS infection.

Animals↗